GLP-1 agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors (that prevent the degradation of the GLP-1) have been approved for the treatment of type 2 diabetes (Trujillo and Nuffer, 2014). This evidence concerns the gene GCG and type 2 diabetes mellitus.